• EyeGene received South Korean regulatory clearance on Nov. 12, 2026, to modify its Phase 2/3 trial of meningococcal conjugate vaccine EG-MCV4.
• The changes add control participants to maintain double-blinding in the Phase 3 safety cohort.
• The study targets 125 participants in Phase 2 and 998 in Phase 3, with completion expected Dec. 31, 2027.
• Phase 2 will guide dose selection; Phase 3 will assess whether EG-MCV4 delivers an immune response comparable to Menveo while evaluating safety.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyeGene Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261112901174), on November 12, 2026, and is solely responsible for the information contained therein.